Matches in SemOpenAlex for { <https://semopenalex.org/work/W3128185551> ?p ?o ?g. }
- W3128185551 endingPage "1651" @default.
- W3128185551 startingPage "1641" @default.
- W3128185551 abstract "The efficacy of a combination of nimotuzumab, a humanized monoclonal antibody to the epidermal growth factor receptor, with chemoradiation in locally advanced head and neck squamous cell carcinoma (HNSCC) was evaluated in a phase II study.Patients with stage III/IV HNSCC received 3-weekly cisplatin 100 mg/m2 for three cycles and weekly nimotuzumab 200 mg for 8 weeks concurrently with radiotherapy. Primary endpoint was best overall response (BOR) and secondary endpoint was progression-free survival (PFS).Thirty-seven patients were included; the majority were Chinese (76%), male (89%), and had stage IVA/IVB HNSCC (92%). BOR of complete and partial response was seen in 22/37 (59%) and 10/37 (27%) patients, respectively. Median PFS was 17.5 months (95% CI: 11.1-54.5) and 3-year PFS was 40.4% (95% CI: 24.3-55.9). The frequency and type of adverse events observed were similar to standard chemoradiation.The combination of nimotuzumab with cisplatin and radiotherapy was safe and achieved high response rates in HNSCC." @default.
- W3128185551 created "2021-02-15" @default.
- W3128185551 creator A5007205435 @default.
- W3128185551 creator A5013437994 @default.
- W3128185551 creator A5015592636 @default.
- W3128185551 creator A5017520870 @default.
- W3128185551 creator A5028592828 @default.
- W3128185551 creator A5029453742 @default.
- W3128185551 creator A5031699071 @default.
- W3128185551 creator A5043046640 @default.
- W3128185551 creator A5059269204 @default.
- W3128185551 creator A5059802213 @default.
- W3128185551 creator A5061589915 @default.
- W3128185551 creator A5071781615 @default.
- W3128185551 creator A5072637653 @default.
- W3128185551 creator A5073819873 @default.
- W3128185551 date "2021-02-05" @default.
- W3128185551 modified "2023-09-26" @default.
- W3128185551 title "Phase <scp>II</scp> study of nimotuzumab ( <scp>TheraCim‐hR3</scp> ) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma" @default.
- W3128185551 cites W1482866244 @default.
- W3128185551 cites W1757407923 @default.
- W3128185551 cites W1974227785 @default.
- W3128185551 cites W2029032030 @default.
- W3128185551 cites W2036005555 @default.
- W3128185551 cites W2073541926 @default.
- W3128185551 cites W2089257078 @default.
- W3128185551 cites W2089663915 @default.
- W3128185551 cites W2100618115 @default.
- W3128185551 cites W2100961085 @default.
- W3128185551 cites W2105499507 @default.
- W3128185551 cites W2108572942 @default.
- W3128185551 cites W2110664940 @default.
- W3128185551 cites W2124391087 @default.
- W3128185551 cites W2139248078 @default.
- W3128185551 cites W2140753782 @default.
- W3128185551 cites W2143680521 @default.
- W3128185551 cites W2145078756 @default.
- W3128185551 cites W2146488048 @default.
- W3128185551 cites W2155384808 @default.
- W3128185551 cites W2157824687 @default.
- W3128185551 cites W2517211727 @default.
- W3128185551 cites W2559848388 @default.
- W3128185551 cites W2625645222 @default.
- W3128185551 cites W2734196292 @default.
- W3128185551 cites W2771191081 @default.
- W3128185551 cites W2775469584 @default.
- W3128185551 cites W2799777523 @default.
- W3128185551 cites W2806122709 @default.
- W3128185551 cites W2890262805 @default.
- W3128185551 cites W2891687048 @default.
- W3128185551 cites W2901263658 @default.
- W3128185551 cites W2901385432 @default.
- W3128185551 cites W2946611948 @default.
- W3128185551 cites W2946851139 @default.
- W3128185551 cites W2947636764 @default.
- W3128185551 cites W3029595057 @default.
- W3128185551 cites W3094325957 @default.
- W3128185551 doi "https://doi.org/10.1002/hed.26635" @default.
- W3128185551 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33547683" @default.
- W3128185551 hasPublicationYear "2021" @default.
- W3128185551 type Work @default.
- W3128185551 sameAs 3128185551 @default.
- W3128185551 citedByCount "6" @default.
- W3128185551 countsByYear W31281855512021 @default.
- W3128185551 countsByYear W31281855512022 @default.
- W3128185551 countsByYear W31281855512023 @default.
- W3128185551 crossrefType "journal-article" @default.
- W3128185551 hasAuthorship W3128185551A5007205435 @default.
- W3128185551 hasAuthorship W3128185551A5013437994 @default.
- W3128185551 hasAuthorship W3128185551A5015592636 @default.
- W3128185551 hasAuthorship W3128185551A5017520870 @default.
- W3128185551 hasAuthorship W3128185551A5028592828 @default.
- W3128185551 hasAuthorship W3128185551A5029453742 @default.
- W3128185551 hasAuthorship W3128185551A5031699071 @default.
- W3128185551 hasAuthorship W3128185551A5043046640 @default.
- W3128185551 hasAuthorship W3128185551A5059269204 @default.
- W3128185551 hasAuthorship W3128185551A5059802213 @default.
- W3128185551 hasAuthorship W3128185551A5061589915 @default.
- W3128185551 hasAuthorship W3128185551A5071781615 @default.
- W3128185551 hasAuthorship W3128185551A5072637653 @default.
- W3128185551 hasAuthorship W3128185551A5073819873 @default.
- W3128185551 hasConcept C121608353 @default.
- W3128185551 hasConcept C126322002 @default.
- W3128185551 hasConcept C143998085 @default.
- W3128185551 hasConcept C197934379 @default.
- W3128185551 hasConcept C203092338 @default.
- W3128185551 hasConcept C2776055544 @default.
- W3128185551 hasConcept C2776530083 @default.
- W3128185551 hasConcept C2776694085 @default.
- W3128185551 hasConcept C2776833033 @default.
- W3128185551 hasConcept C2778239845 @default.
- W3128185551 hasConcept C2778496288 @default.
- W3128185551 hasConcept C2779438470 @default.
- W3128185551 hasConcept C29730261 @default.
- W3128185551 hasConcept C31760486 @default.
- W3128185551 hasConcept C509974204 @default.
- W3128185551 hasConcept C535046627 @default.
- W3128185551 hasConcept C71924100 @default.